Chalifah Fatihah
Jakarta, Indonesia – Mayapada Hospital Jakarta Selatan is set to enhance its comprehensive cancer care services with the upcoming integration of Positron Emission Tomography-Computed Tomography (PET-CT) and Single Photon Emission Computed Tomography-Computed Tomography (SPECT-CT) scanning technologies. Scheduled for launch in April 2026 at the first floor of Tower 2, this strategic expansion underscores the hospital’s commitment to leveraging cutting-edge medical advancements for earlier, more precise, and personalized cancer detection and treatment.
The introduction of PET-CT and SPECT-CT represents a significant leap forward in nuclear medicine, offering capabilities far beyond conventional imaging techniques. These advanced diagnostic tools are crucial in addressing the complexities of modern cancer management, particularly in cases where traditional methods yield ambiguous results regarding the presence and activity of cancerous cells.
The Power of PET-CT and SPECT-CT in Cancer Diagnosis
PET-CT is a sophisticated fusion of two powerful imaging technologies: Positron Emission Tomography (PET) and Computed Tomography (CT). PET imaging excels at assessing the metabolic activity and functional status of cells, identifying areas of heightened cellular activity that are characteristic of cancer. CT imaging, on the other hand, provides detailed anatomical and structural information of the body. The synergistic combination of these two modalities allows for the precise localization of metabolically active cancerous cells within the anatomical context of the body.
"PET-CT plays a pivotal role in detecting cancer at an earlier stage compared to conventional imaging," stated Dr. Yustia Tuti, SpKN, a specialist in Nuclear Medicine at Mayapada Hospital Jakarta Selatan. "This early detection is paramount, as it directly influences the speed and effectiveness of subsequent treatment interventions."
Beyond initial detection, PET-CT is instrumental in accurately staging cancer. The determination of cancer stage, which describes the extent of the disease’s spread, is a critical factor in formulating the most appropriate treatment plan. "With PET-CT scans, clinicians can ascertain the full extent of cancer dissemination, including its involvement of lymph nodes or other organs, thereby achieving a more precise staging," Dr. Yustia explained. This granular understanding of cancer spread enables oncologists to select the most effective therapeutic strategies, ranging from surgery and chemotherapy to radiotherapy and targeted therapies.
Revolutionizing Treatment Planning and Response Evaluation
The utility of PET-CT extends significantly into the realm of treatment planning. The detailed information gleaned from these scans serves as a foundational basis for determining a patient’s treatment needs. This includes guiding decisions on surgical interventions, optimizing chemotherapy regimens, planning radiotherapy with enhanced precision, and even identifying the necessity for combination therapies. Furthermore, PET-CT helps delineate specific target areas for therapy, ensuring that treatments are delivered more effectively and with minimized risk of damage to healthy tissues.
A crucial aspect of cancer management is the continuous evaluation of treatment response. PET-CT excels in this area by assessing the efficacy of therapy not merely based on changes in tumor size, but by directly measuring the metabolic activity of cancer cells. This functional assessment allows physicians to discern the true impact of the treatment much earlier, enabling timely adjustments to the therapeutic strategy if the cancer is not responding as anticipated.
Detecting Recurrence and Expanding Applications
The ability of PET-CT to detect cancer recurrence is another significant advantage. Dr. Yustia elaborated, "PET-CT scans are beneficial in identifying recurrent cancers, particularly when symptoms resurface, other diagnostic tests are inconclusive, or tumor markers show an increase." Early detection of recurrence allows for prompt re-intervention, potentially improving treatment outcomes and increasing the likelihood of successful therapy.
The application of PET-CT scans is widespread across various cancer types, including breast, lung, colorectal, head and neck, lymphoma, cervical, and ovarian cancers. In specific cases, specialized radiopharmaceuticals enable its use in diagnosing prostate cancer as well. "PET-CT scans are no longer solely for diagnosis; they have become an integral component of treatment evaluation and planning, including for radiopharmaceutical therapy and precision radiotherapy, ensuring that cancer management is more targeted and personalized," Dr. Yustia noted.
The Growing Significance of Nuclear Medicine in Indonesia
While cancer remains a formidable global health challenge, advanced medical technologies like PET-CT are proving indispensable in the fight against it. However, the availability of such sophisticated equipment in Indonesia has historically been limited. The introduction of PET-CT and SPECT-CT at Mayapada Hospital Jakarta Selatan signifies a crucial step towards making these advanced diagnostic capabilities more accessible within the country.
Mayapada Hospital’s Commitment to Integrated Oncology Care
The upcoming PET-CT and SPECT-CT services will be seamlessly integrated into the existing comprehensive Oncology Center at Mayapada Hospital Jakarta Selatan. This center is dedicated to providing continuous and holistic care for tumor and cancer patients, supported by a multidisciplinary team of physicians, an active Tumor Board that formulates precise treatment plans, and dedicated Patient Navigators who guide patients throughout their treatment journey.
The inclusion of SPECT-CT technology, which also utilizes radioactive tracers to create detailed images, further enhances diagnostic capabilities, particularly in areas like bone imaging, infection detection, and cardiac assessments, complementing the already powerful PET-CT.
Accessing Advanced Cancer Diagnostics
Patients seeking advanced cancer detection and diagnostic services using PET-CT or SPECT-CT are encouraged to consult with a physician at Mayapada Hospital. Scheduling a consultation can be done by contacting the hospital’s call center at 150770 or through the Mayapada Hospital mobile application, MyCare.
The MyCare application also serves as a valuable resource for information on the Oncology Center and other specialized services offered by Mayapada Hospital, including health articles and tips. Additionally, the app features a Personal Health module that supports healthy lifestyle choices by tracking vital metrics such as heart rate, step count, calorie expenditure, and Body Mass Index (BMI).
The strategic investment by Mayapada Hospital in these advanced imaging technologies underscores its dedication to providing world-class healthcare and improving patient outcomes in the ongoing battle against cancer. The integration of PET-CT and SPECT-CT is expected to elevate the standard of cancer care in Indonesia, offering patients access to diagnostic precision and treatment planning that is on par with global benchmarks. This development is particularly significant given the increasing incidence of cancer in Indonesia, highlighting the urgent need for accessible, high-quality diagnostic and therapeutic services.
